BCBSNC to implement Callidus Software's Monaco Suite

NewsGuard 100/100 Score

Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), today announced that Blue Cross Blue Shield of North Carolina (BCBSNC), has selected the Callidus Monaco Suite to manage sales performance and incentive compensation programs. Under the enterprise class SaaS agreement, signed in the third quarter of 2009, BCBSNC will use the Callidus Monaco Suite for its 4,000 brokers.

"We continue to see strong momentum in all our lines of business," said Jeff Saling, senior vice president of global sales at Callidus Software. "The adoption of Callidus Software's SaaS solutions at the large enterprise level shows that the on-demand revolution is on fire and no longer a mid-market phenomenon."

The Callidus Monaco Suite provides an end-to-end performance management platform. It enables businesses to optimize the entire sales lifecycle from sales on-boarding, to quota and plan deployment, and payment. This helps deliver a high ROI in a very short period of time. The company's solutions give actionable insight into sales execution and channel operations thereby providing the tools to fine-tune sales performance.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
When mass spectrometry redefines the pharma industry